John Granton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11479920/publications.pdf

Version: 2024-02-01

117625 91884 8,103 69 34 69 h-index citations g-index papers 71 71 71 8217 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension: the Toronto experience. Annals of Cardiothoracic Surgery, 2022, 11, 133-142. | 1.7 | 6 |
| 2 | Outcome after pulmonary endarterectomy for segmental chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 696-707.e4. | 0.8 | 7 |
| 3 | Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure. Journal of Heart and Lung Transplantation, 2022, 41, 773-779. | 0.6 | 9 |
| 4 | ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194. | 0.6 | 17 |
| 5 | Pulmonary arterial hypertension in pregnancy—a systematic review of outcomes in the modern era. Pulmonary Circulation, 2021, 11, 1-9. | 1.7 | 34 |
| 6 | Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. Journal of Pain and Symptom Management, 2020, 59, 932-943. | 1.2 | 10 |
| 7 | Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine, 2020, 19, 100249. | 7.1 | 150 |
| 8 | In-House, Overnight Physician Staffing: A Cross-Sectional Survey of Canadian Adult ICUs. Critical Care Medicine, 2020, 48, e1203-e1210. | 0.9 | 2 |
| 9 | Importance of computed tomography in defining segmental disease in chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2020, 6, 00461-2020. | 2.6 | 8 |
| 10 | Temporal shifts in fluid in pulmonary hypertension with and without sleep apnea. Journal of Sleep Research, 2019, 28, e12863. | 3.2 | 4 |
| 11 | Pharmacology of theÂPulmonary Circulation. , 2019, , 165-179. | | O |
| 12 | Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients*. Critical Care Medicine, 2019, 47, 918-925. | 0.9 | 58 |
| 13 | Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908. | 6.7 | 142 |
| 14 | Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 337-347. | 5.6 | 115 |
| 15 | Serial assessment of systemic levels of proinflammatory cytokines in septic shock patients treated with allogeneic mesenchymal stem cells. Cytotherapy, 2017, 19, e5. | 0.7 | 1 |
| 16 | Cellular immunotherapy for septic shock (CISS): a phase I trial. Cytotherapy, 2017, 19, e3-e4. | 0.7 | 2 |
| 17 | Lung Transplantation for Pulmonary Hypertension and Strategies to Bridge to Transplant. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 701-710. | 2.1 | 5 |
| 18 | Symptoms Are More Useful Than Echocardiography in Patient Selection forÂPulmonary Endarterectomy. Annals of Thoracic Surgery, 2017, 104, 1179-1185. | 1.3 | 21 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respiratory Research, 2017, 4, e000183. | 3.0 | 148 |
| 20 | Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: New Horizons in the Interventional Management of Pulmonary Embolism. Techniques in Vascular and Interventional Radiology, 2017, 20, 206-215. | 1.0 | 5 |
| 21 | Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults. Journal of Critical Care, 2016, 31, 31-35. | 2.2 | 85 |
| 22 | Risk factors for mortality in patients admitted to intensive care units with pneumonia. Respiratory Research, 2016, 17, 80. | 3.6 | 39 |
| 23 | Role of extracorporeal life support after pulmonary endarterectomy: a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 74-78. | 1.1 | 16 |
| 24 | A Case of Pulmonary Arterial Hypertension Associated with Adult Hemophagocytic Lymphohistiocytosis. Pulmonary Circulation, 2016, 6, 614-615. | 1.7 | 1 |
| 25 | Recall of ICU Stay in Patients Managed With a Sedation Protocol or a Sedation Protocol With Daily Interruption. Critical Care Medicine, 2015, 43, 2180-2190. | 0.9 | 36 |
| 26 | Prevalence, Risk Factors, and Outcomes of Delirium in Mechanically Ventilated Adults*. Critical Care Medicine, 2015, 43, 557-566. | 0.9 | 268 |
| 27 | Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. Drug Safety, 2015, 38, 419-435. | 3.2 | 25 |
| 28 | Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 369-375. | 0.6 | 37 |
| 29 | Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension. Circulation Research, 2015, 117, 645-654. | 4.5 | 120 |
| 30 | Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 965-973. | 5.6 | 76 |
| 31 | Critical care capacity in Canada: results of a national cross-sectional study. Critical Care, 2015, 19, 133. | 5.8 | 55 |
| 32 | Patient safety, resident well-being and continuity of care with different resident duty schedules in the intensive care unit: a randomized trial. Cmaj, 2015, 187, 321-329. | 2.0 | 80 |
| 33 | Riociguat for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine, 2015, 9, 679-695. | 2.5 | 15 |
| 34 | A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung. PLoS ONE, 2015, 10, e0134958. | 2.5 | 41 |
| 35 | Metabolomic Heterogeneity of Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e88727. | 2.5 | 111 |
| 36 | Long-term outcomes after pulmonary embolism. Blood Coagulation and Fibrinolysis, 2014, 25, 407-415. | 1.0 | 49 |

| # | Article | IF | Citations |
|----|--|------|-----------|
| 37 | De novo synthesize of bile acids in pulmonary arterial hypertension lung. Metabolomics, 2014, 10, 1169-1175. | 3.0 | 35 |
| 38 | Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72. | 2.8 | 596 |
| 39 | Management of Severe Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 700-713. | 2.1 | 27 |
| 40 | Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Critical Care, 2013, 17, R117. | 5.8 | 43 |
| 41 | Daily Sedation Interruption in Mechanically Ventilated Critically Ill Patients Cared for With a Sedation Protocol. JAMA - Journal of the American Medical Association, 2012, 308, 1985. | 7.4 | 402 |
| 42 | Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. International Journal of Hematology, 2012, 95, 445-450. | 1.6 | 15 |
| 43 | Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2012, 7, e47559. | 2.5 | 906 |
| 44 | Agreement in electrocardiogram interpretation in patients with septic shock*. Critical Care Medicine, 2011, 39, 2080-2086. | 0.9 | 34 |
| 45 | Recall of intensive care unit stay in patients managed with a sedation protocol or a sedation protocol with daily sedative interruption: A pilot study. Journal of Critical Care, 2011, 26, 127-132. | 2.2 | 32 |
| 46 | Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1114-1124. | 5.6 | 259 |
| 47 | The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care, 2010, 25, 287-293. | 2.2 | 117 |
| 48 | Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Practice Guideline. Canadian Respiratory Journal, 2010, 17, 301-334. | 1.6 | 68 |
| 49 | Under Pressure. New England Journal of Medicine, 2010, 362, 449-454. | 27.0 | 3 |
| 50 | Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. International Journal of Cardiology, 2010, 144, 373-378. | 1.7 | 64 |
| 51 | Outcomes in pulmonary hypertension: Beyond 40 metres. Canadian Journal of Cardiology, 2010, 26, 12B-16B. | 1.7 | 1 |
| 52 | Feasibility of Internet-Based Health-Related Quality of Life Data Collection in a Large Patient Cohort. Journal of Medical Internet Research, 2010, 12, e35. | 4.3 | 18 |
| 53 | Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. International Journal of Cardiology, 2008, 127, 27-32. | 1.7 | 215 |
| 54 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factors. Critical Care, 2008, 12, R32. | 5.8 | 68 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin <subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle> . Archives of Internal Medicine, 2008, 168, 1805. | 3.8 | 133 |
| 56 | A randomized trial of daily awakening in critically ill patients managed with a sedation protocol: A pilot trial*. Critical Care Medicine, 2008, 36, 2092-2099. | 0.9 | 107 |
| 57 | Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Canadian Respiratory Journal, 2008, 15, 77-83. | 1.6 | 26 |
| 58 | Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival. Circulation Research, 2006, 98, 209-217. | 4.5 | 287 |
| 59 | In-house, overnight physician staffing: A cross-sectional survey of Canadian adult and pediatric intensive care units*. Critical Care Medicine, 2006, 34, 1674-1678. | 0.9 | 83 |
| 60 | Update of early respiratory failure in the lung transplant recipient. Current Opinion in Critical Care, 2006, 12, 19-24. | 3.2 | 32 |
| 61 | Pulmonary hypertension after pulmonary emboli: an underrecognized condition. Cmaj, 2006, 174, 1706-1706. | 2.0 | 11 |
| 62 | Bosentan Therapy in Patients With Eisenmenger Syndrome. Circulation, 2006, 114, 48-54. | 1.6 | 773 |
| 63 | Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. Journal of Critical Care, 2005, 20, 364-372. | 2.2 | 70 |
| 64 | Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. Canadian Respiratory Journal, 2005, 12, 303-315. | 1.6 | 5 |
| 65 | Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters. Journal of Heart and Lung Transplantation, 2004, 23, 96-104. | 0.6 | 51 |
| 66 | High-Frequency Oscillatory Ventilation in Adults. Chest, 2004, 126, 518-527. | 0.8 | 1,201 |
| 67 | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT): A Pilot Study Blood, 2004, 104, 1784-1784. | 1.4 | 14 |
| 68 | High-Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome in Adults. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 801-808. | 5.6 | 588 |
| 69 | Use of a screen log to audit patient recruitment into multiple randomized trials in the intensive care unit. Critical Care Medicine, 2000, 28, 867-871. | 0.9 | 20 |